Mycobacterial carrier and antitumour activity of the combination: BCG-cyclophosphamide.
Immuno-chemical studies of various BCG components show that the anti-tumour effect of BCG plus cyclophosphamide is attributed to the interaction between two bacterial fractions and the cytotoxic drug, cyclophosphamide(CY). One of the bacterial fraction is a chemically-well-defined peptidoglycopeptide fraction(PGLF) with immuno-stimulating activity and the other is a bacterial residue (BR) completely devoid of immuno-stimulating activity. Nevertheless, BR, a powerful adsorbant, was found to be a "mycobacterial carrier" of both the active bacterial molecule (PGLF) and the cytotoxic drug (CY).